1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,550 | 1,590 | 16:31 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.03. | BIOCYTOGEN-B (02315): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 | - | HKEx | ||
| 14.03. | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | 4 | HKEx | ||
| 28.02. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT THE DEEPSEEK PLATFORM LOCALIZED DEPLOYMENT AND UPGRADE IN RESEARCH AND DEVELOPMENT STRATEGY OF ANTIBODY DRUGS ... | 1 | HKEx | ||
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 21.02. | BIOCYTOGEN-B (02315): ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE YEAR ENDED DECEMBER 31, 2024 | 1 | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): POSITIVE PROFIT ALERT | 2 | HKEx | ||
| 09.01. | Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment | 280 | Business Wire | Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to SOTIO Biotech, a... ► Artikel lesen | |
| 09.01. | SOTIO Biotech: SOTIO Advances Colorectal Cancer ADC Program, SOT109, and Licenses Fully Human Antibodies from Biocytogen for Novel Tumor Target | 308 | Business Wire | SOT109 will leverage antibodies generated with Biocytogen's proprietary RenMab platform as backbone of ADC for colorectal cancer and other gastrointestinal cancers SOTIO Biotech, a clinical-stage... ► Artikel lesen | |
| 08.01. | Biocytogen und Acepodia bündeln ihre Kräfte, um bispezifische Antikörper und Dual-Payload-ADCs zur Behandlung komplexer Tumore voranzutreiben | 306 | Business Wire | Zusammenarbeit initiiert Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten mit doppelter Nutzlast (BsAD2Cs)
Biocytogens RenLite® trifft auf Acepodias AD2C für präzise onkologische... ► Artikel lesen | |
| 07.01. | Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors | 405 | Business Wire | Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs)
Biocytogen's RenLite® meets Acepodia's AD2C for precision oncology solutions
Biocytogen... ► Artikel lesen | |
| 06.01. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT SHARE PURCHASE BY TRUSTEE PURSUANT TO SHARE AWARD SCHEME | 2 | HKEx | ||
| 18.12.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen gibt bekannt, dass Adcendo ApS die Antikörperoption ausübt, um die ADC-Entwicklung zu beschleunigen | 390 | Business Wire | Adcendo übt seine Option aus, die vollständig humanen Antikörper von Biocytogen zu nutzen, um seine ADC-Pipeline für Krebserkrankungen mit hohem ungedecktem medizinischen Bedarf weiter auszubauen... ► Artikel lesen | |
| 16.12.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development | 295 | Business Wire | Adcendo exercises its option to utilize Biocytogen's fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need
This collaboration further validates... ► Artikel lesen | |
| 11.11.24 | Ideaya pushes ahead with Biocytogen bispecific ADC bet | 2 | FierceBiotech | ||
| 11.11.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise | 412 | Business Wire | IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen's potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034)... ► Artikel lesen | |
| 11.11.24 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT IDEAYA'S NOMINATION OF DEVELOPMENT CANDIDATE IDE034, A POTENTIAL FIRST-IN-CLASS B7H3/PTK7 TOPO-I-PAYLOAD ... | 3 | HKEx | ||
| 31.07.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program | 352 | Business Wire | Biocytogen granted IDEAYA an option for an exclusive worldwide license for potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program
B7H3/PTK7... ► Artikel lesen | |
| 16.07.24 | SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 336 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen | |
| 16.07.24 | SOTIO Biotech: SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 344 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen | |
| 21.06.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen erhält US-Patent für seine gemeinsame Leichtketten-Mausplattform RenLite | 474 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) gab jetzt die Erteilung eines Patents durch das United States Patent and Trademark Office (USPTO) für die von Biocytogen... ► Artikel lesen | |
| 21.06.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Awarded U.S. Patent for RenLite Common Light Chain Mouse Platform | 343 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLitefully human common... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,700 | -0,57 % | XFRA MDG1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMEDIGENE AG NA O.N.... ► Artikel lesen | |
| BIOFRONTERA | 2,405 | -3,22 % | Top-Zock 2025: Formycon, Biofrontera oder BB Biotech? | Auf der Suche nach unserem Top-Zock 2025 haben wir unzählige Small- und Nano-Cap-Titel analysiert. Ein Wert sticht dabei mit einem überragenden Chance-Risiko-Profil über die nächsten Monate heraus.... ► Artikel lesen | |
| CLINUVEL | 5,900 | -6,79 % | Biocurious: While other biotechs scratch around for cash, Clinuvel is accused of having too much | ||
| EDITAS MEDICINE | 1,019 | -0,20 % | Editas Medicine, Inc.: Editas Medicine Announces Chief Financial Officer Transition | Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.... ► Artikel lesen | |
| BLUEBIRD BIO | 4,340 | -2,25 % | Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps | ||
| CELLECTAR BIOSCIENCES | 0,254 | -5,22 % | Cellectar Biosciences: Multibagger mit Ansage? | Cellectar Biosciences (WKN: A3DQSD) heißt unsere Top-Spekulation der Stunde. Das auf Radiopharmaka gegen Krebs spezialisierte Biotechunternehmen konnte gestern eine wichtige Einigung mit der US-Gesundheitsbehörde... ► Artikel lesen | |
| ASEP MEDICAL | 0,042 | +0,96 % | ASEP Medical Holdings Inc: ASEP to issue 26.87M shares for debt of $1.34M | ||
| CARDIFF ONCOLOGY | 2,500 | -3,85 % | Lucid Capital Markets sets $14 target on Cardiff Oncology stock | ||
| CLEAN HARBORS | 171,50 | -4,72 % | Clean Harbors Aktie: Unsichere Gefilde voraus? | Die Clean Harbors Aktie setzte am 22. März 2025 ihren negativen Kursverlauf fort und notierte bei 180,63 Euro. Der Umweltdienstleister verzeichnete damit einen Tagesverlust von 0,21 Prozent. Besonders... ► Artikel lesen | |
| SPERO THERAPEUTICS | 0,585 | +1,39 % | Spero halts development on another antibiotic in latest reprioritization | ||
| MESOBLAST | 1,000 | -7,41 % | Mesoblast Limited: First Three Children to Commence Treatment With Ryoncil | NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,340 | -3,41 % | CSTONE PHARMA-B (02616): PLACING OF NEW SHARES UNDER GENERAL MANDATE | ||
| PROTALIX BIOTHERAPEUTICS | 2,218 | -5,78 % | Amended: Protalix Annual Earnings Fall | JERUSALEM (dpa-AFX) - (Amended: Recasting the story to correct the period, revenue)Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, Monday reported a decline in earnings for... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 24,200 | +12,04 % | Palvella Therapeutics Inc.: Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update | Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical... ► Artikel lesen | |
| MERSANA THERAPEUTICS | 0,280 | -1,20 % | Mersana Therapeutics Aktie: Ein negativer Trend? | Biopharmaunternehmen verzeichnet ermutigende Ergebnisse für Krebswirkstoff Emi-Le, erweiterte FDA-Anerkennung und verbesserte Quartalszahlen trotz Börsenschwäche Die Biotechnologiefirma Mersana Therapeutics... ► Artikel lesen |
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,550 Euro und damit +2,65 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.
